Expertise in
12
conditions

Dr. Ehsan Malek

Hematology
University Hospitals Case Medical Center
11100 Euclid Ave, 
Cleveland, OH 
Accepting New Patients
Offers Telehealth
Expertise in
12
conditions
University Hospitals Case Medical Center
11100 Euclid Ave, 
Cleveland, OH 

Overview

Ehsan Malek is a Hematologist practicing medicine in Cleveland, Ohio.

Dr. Malek is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Plasmacytoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 69 peer reviewed articles and participating in 9 clinical trials. Dr. Malek is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in OH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

University Hospitals Case Medical Center
11100 Euclid Ave, Cleveland, OH 44106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma
A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2026
Intervention Type: Biological, Drug
Study Drugs: Hiltonol, Citarinostat, Lenalidomide, PVX-410
Study Phase: Phase 1
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
Enrollment Status: Completed
Publish Date: September 09, 2025
Intervention Type: Other, Biological
Study Drug: Isatuximab
Study Phase: Phase 2
A Phase 1b Trial of Vactosertib in Combination With Pomalidomide (POM) in Relapsed or Relapsed and Refractory Multiple Myeloma (RRMM)
A Phase 1b Trial of Vactosertib in Combination With Pomalidomide (POM) in Relapsed or Relapsed and Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: Vactosertib, Pomalidomide
Study Phase: Phase 1
Mycobiome Supporting Diet (MSD) to Reduce Gastrointestinal (GI) Toxicity Associated With Autologous Stem Cell Transplant (ASCT) For Patients With Multiple Myeloma (MM)
Mycobiome Supporting Diet (MSD) to Reduce Gastrointestinal (GI) Toxicity Associated With Autologous Stem Cell Transplant (ASCT) For Patients With Multiple Myeloma (MM)
Enrollment Status: Withdrawn
Publish Date: April 26, 2024
Intervention Type: Behavioral
Study Phase: Not Applicable
A Pilot Study to Assess Impact of Low Dose Melphalan on Disease Burden Measured by Next Generation Sequencing Before Autologous Hematopoietic Cell Transplant (AHCT) for Multiple Myeloma Patients
A Pilot Study to Assess Impact of Low Dose Melphalan on Disease Burden Measured by Next Generation Sequencing Before Autologous Hematopoietic Cell Transplant (AHCT) for Multiple Myeloma Patients
Enrollment Status: Withdrawn
Publish Date: April 02, 2024
Intervention Type: Drug, Device
Study Phase: Early Phase 1
A Pilot Study of Dendritic Cell DKK1 Vaccine for Patients With Monoclonal Gammopathy and Stable or Smoldering Myeloma
A Pilot Study of Dendritic Cell DKK1 Vaccine for Patients With Monoclonal Gammopathy and Stable or Smoldering Myeloma
Enrollment Status: Withdrawn
Publish Date: August 18, 2023
Intervention Type: Biological
Study Drug: DKK1
Study Phase: Early Phase 1
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 26, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 2
A Phase I/II Study of MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Phase I/II Study of MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: December 11, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

69 Total Publications

Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma.
Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma.
Journal: JCO clinical cancer informatics
Published: March 20, 2026
Similar Doctors
Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required
Before you request

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (0.6 miles away)
866-223-8100
Languages Spoken:
English, German, Polish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jaroslaw Maciejewski is a Hematologist practicing medicine in Cleveland, Ohio. Dr. Maciejewski is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Aplastic Anemia, Paroxysmal Cold Hemoglobinuria, Bone Marrow Transplant, and Splenectomy. Dr. Maciejewski is board certified in American Board Of Internal Medicine, 2001. Dr. Maciejewski is currently accepting new patients.

Expertise in
24
conditions
Dr. Eric D. Hsi
Hematology
Expertise in
24
conditions
Dr. Eric D. Hsi
Hematology
Referral may be required

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (0.8 miles away)
216-444-5230
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Eric Hsi is a Hematologist practicing medicine in Cleveland, Ohio. Dr. Hsi is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Splenectomy. Dr. Hsi is currently accepting new patients.

Expertise in
28
conditions
Dr. Anjali S. Advani
Hematology | Oncology
Expertise in
28
conditions
Dr. Anjali S. Advani
Hematology | Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (0.6 miles away)
866-223-8100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anjali Advani is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Advani is highly rated in 28 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Advani is board certified in American Board Of Internal Medicine, 2003. Dr. Advani is currently accepting new patients.

Frequently Asked Questions about Dr. Ehsan Malek

How do I make an appointment with Dr. Ehsan Malek?

You can book an appointment with Dr. Ehsan Malek by calling their office at 216-844-1000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ehsan Malek a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ehsan Malek is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ehsan Malek specialize in?

While Dr. Ehsan Malek is a Hematology, they have specific expertise in Multiple Myeloma, Smoldering Multiple Myeloma, and Plasmacytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Ehsan Malek participate in research or clinical trials?

Yes. Dr. Ehsan Malek has published 69 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Ehsan Malek's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ehsan Malek accept my insurance?

Dr. Ehsan Malek accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 216-844-1000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Malek's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile